Sep 9, 2026 07:01AM
Sep 9, 2026 07:00AM
Aug 11, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 07:00AM
May 14, 2026 07:00AM
Apr 27, 2026 11:59AM AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
Apr 22, 2026 08:30AM
Apr 14, 2026 03:30AM
Apr 14, 2026 03:30AM
Mar 27, 2026 07:00AM
Mar 10, 2026 05:31PM
Feb 16, 2026 10:15AM
Feb 5, 2026 09:26AM The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Jan 12, 2026 07:08AM
Jan 12, 2026 07:00AM
Jan 6, 2026 09:00AM
Jan 6, 2026 09:00AM
Dec 8, 2025 04:06PM
Dec 8, 2025 04:05PM
Dec 8, 2025 08:36AM Autolus presents pediatric data for obe-cel at ASH meeting
Dec 8, 2025 08:35AM
Nov 25, 2025 04:00AM
Nov 12, 2025 07:00AM
Nov 3, 2025 09:05AM
Oct 27, 2025 07:00AM
Oct 20, 2025 07:00AM
Oct 20, 2025 07:00AM Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
Aug 12, 2025 07:00AM
Jul 31, 2025 10:00AM
Jul 21, 2025 07:01AM
Jul 21, 2025 07:00AM
Jun 30, 2025 05:31PM
Jun 27, 2025 11:31AM
Jun 12, 2025 02:00AM Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
Jun 12, 2025 02:00AM
May 29, 2025 04:05PM
May 23, 2025 08:31AM
May 23, 2025 08:30AM
May 14, 2025 09:30AM
May 8, 2025 07:00AM
Apr 25, 2025 12:07PM Autolus Therapeutics (AUTL) Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblast
Apr 25, 2025 12:06PM
Apr 23, 2025 04:05PM
Apr 23, 2025 04:05PM
Apr 22, 2025 07:00AM
Apr 16, 2025 01:00AM
Apr 2, 2025 07:00AM
Apr 1, 2025 07:00AM Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
Apr 1, 2025 07:00AM

330,674 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All